Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Panna Sharma
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 16
- Beta
- 2.30
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -22.87
Financials
Net Income
$-7.07MEBITDA
$-7.07MFree Cash Flow
$-2.94MEPS (diluted)
$-0.57Shares Outstanding (diluted)
12.42M+99.8%Operating Expenses
$3.51MCash & Debt
$7.36MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-17.12M | $-1.57 |
| 2024 | $0.00 | $-20.78M | $-1930.92 |
| 2023 | $0.00 | $-15.96M | $-1.47 |
| 2022 | $0.00 | $-14.26B | $-1.31 |
| 2021 | $0.00 | $-12.36M | $-1.13 |
| 2020 | $0.00 | $-5.91M | $-0.95 |
| 2019 | $0.00 | $-2.43M | $-0.39 |
| 2018 | $0.00 | $-1.73M | $-0.28 |
Valuation
LTRNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70-56.25%Social Signal Score
Mentions (4)
- Newsseekingalpha.com·12d ago·Positive
Lantern Pharma Inc. (LTRN) Discusses Open-Medicine AI Platform Roadmap, Business Model, and Value Proposition for Therapeutic Development Transcript Lantern Pharma Inc. (LTRN) Discusses Open-Medicine AI Platform Roadmap, Business Model, and Value Proposition for Therapeutic Development Transcript
View source ↗ - Newsbusinesswire.com·14d ago·Negative
Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an AI‑driven precision oncology company transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 18/500,032, titled "Method for Treating Blood Cancers," with clai…
View source ↗ - Newsseekingalpha.com·52d ago·Positive
Lantern Pharma Inc. (LTRN) Q2 2026 Earnings Call Transcript Lantern Pharma Inc. (LTRN) Q2 2026 Earnings Call Transcript
View source ↗ - Newsbusinesswire.com·53d ago·Neutral
Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update DALLAS--(BUSINESS WIRE)--Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update.
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.35 per share
Typical surprise +15.2% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-0.57 vs $-0.38miss
- Fri, May 15$-0.30 vs $-0.36beat
- Mon, Mar 30$-0.36 vs $-0.46beat
- Wed, Nov 12$-0.39 vs $-0.46beat
- Wed, Aug 13$-0.40 vs $-0.53beat
- Thu, May 15$-0.42 vs $-0.49beat
Estimates and results for LTRN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by LTRN officers and directors.
- Bought
- $420k
- Sold
- $925k
4 trades
60 trades
- Schalop Lee Troybought
- Schalop Lee Troybought
- Keyser D Jeffreybought
- Keyser D Jeffreybought
- Fletcher Aaron G.l.sold
- Fletcher Aaron G.l.sold
- Fletcher Aaron G.l.sold
- Fletcher Aaron G.l.sold
36 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in LTRN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.